SCHEMBL325232

SCHEMBL325232

O=C(OCc1cc(Cl)ccc1Cl)N1C=Cc2ccccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 1/20 0.46
DRD2 P14416 2/20 0.38
DRD3 P35462 1/20 0.38
KCNH2 Q12809 1/20 0.38
HRH1 P35367 1/20 0.38
HDAC8 Q9BY41 3/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
DRD4 P21917 1/20 0.35
XIAP P98170 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35
PTGDR2 Q9Y5Y4 3/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
GPBAR1 Q8TDU6 3/20 0.34
MRGPRX4 Q96LA9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323930 0.91 HSD17B3 (0.46) HSD17B3HDAC8HDAC3HDAC1HDAC2
SCHEMBL324441 0.91 HSD17B3 (0.43) HSD17B3HRH1HDAC8HDAC3HDAC1
SCHEMBL323904 0.89 ALDH1A1 (0.37) HSD17B3HDAC3PTGDR2TAS1R3TAS1R1
SCHEMBL324263 0.88 L3MBTL1 (0.40) HSD17B3HDAC3
SCHEMBL324120 0.83 P2RX4 (0.46) HSD17B3PTGDR2
SCHEMBL323083 0.83 IDO1 (0.38) HSD17B3HDAC3PTGDR2
SCHEMBL325206 0.83 HCAR2 (0.43) HSD17B3PTGDR2
SCHEMBL324646 0.81 HSD17B3 (0.38) HSD17B3HDAC3
SCHEMBL323140 0.81 MMP2 (0.42) HSD17B3HDAC3XIAPPTGDR2TAS1R3
SCHEMBL323574 0.80 GRIN2B (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 HSD17B3 967/4885DRD2 305/4885DRD3 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.